Grants
88 Grants
Investigating the Impact of API Purity, Lipid Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles
Sponsor: DHHS/FDA/Food and Drug Administration
Authors: Xiuling Lu
Funding: $1,530,889
2023-09-22 - 2027-09-21
In Vitro and In Vivo Assessment of Ophthalmic Ointments for Generic Product Equivalence
Sponsor: DHHS/FDA/Food and Drug Administration
Authors: Xiuling Lu
Funding: $1,141,038
2018-09-11 - 2022-12-10
Assessing Long-Acting Injectable Formulations Using in Vivo Imaging
Sponsor: DHHS/FDA/Food and Drug Administration
Authors: Xiuling Lu
Funding: $1,131,742
2020-09-30 - 2024-09-29
Activatable Nanoparticles for Radiotherapy of Metastatic Ovarian Cancer
Sponsor: American Cancer Society
Authors: Xiuling Lu
Funding: $792,000
2015-07-01 - 2020-12-31
Novel LAAM Formulations to Treat Opioid Use Disorder
Sponsor: DHHS/NIH/National Institute on Drug Abuse/Virginia Commonwealth University
Authors: Xiuling Lu
Funding: $443,068
2019-09-30 - 2022-08-31
Dissolution Methods for Predicting Bioequivalence of Ocular Semi-Solid Formulations
Sponsor: DHHS/FDA/Food and Drug Administration
Authors: Xiuling Lu
Funding: $435,880
2014-09-15 - 2017-08-31
Cryopreservation of T cells with exploration of cell freeze drying
Sponsor: Janssen Pharmaceuticals
Authors: Xiuling Lu
Funding: $409,797
2020-11-20 - 2023-11-20
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer
Sponsor: DHHS/NIH/National Cancer Institute/NAMI Therapeutics
Authors: Xiuling Lu
Funding: $357,855
2022-08-19 - 2025-07-31
Chromatin interaction, epigenomics, and transcriptional response to drug induction
Sponsor: University of Connecticut and Jackson Laboratory
Authors: xiaobo zhong, Xiuling Lu, Yijun Ruan, Guoliang Li
Funding: $250,000
2013-10-01 - 2018-09-30
Polymer-based Nanocarrier Platform for Improving Efficacy and Safety of Potent Chemotherapeutic Agents
Sponsor: UConn Academic Plan Grant
Authors: Xiuling Lu, Rajeswari Kasi, Bruce Liang, Jose E Manautou, Ming-Hui Chen
Funding: $240,000
2015-07-01 - 2018-06-30
CPPR: Understanding the Nanoparticle Structure Changes Post Lyophilization and Storage of mRNA Lipid Nanoparticles
Sponsor: Mixed Sources
Authors: Xiuling Lu
Funding: $200,000
2025-01-01 - 2026-12-31
CPPR: Impact of Lyoprotectants and Residual Moisture on Product Stability of Freeze-Dried mRNA-Lipid Nanoparticles
Sponsor: Mixed Sources
Authors: Xiuling Lu
Funding: $160,000
2023-01-01 - 2025-12-31
Intraperitoneal Delivery of Targeted Nanoparticles for Metastatic Ovarian Cancer
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
Funding: $158,000
2014-12-01 - 2016-11-30
CPPR: Impact of Controlled Ice Nucleation and Cell Dehydration on T-cell Cryopreservation
Sponsor: Mixed Sources
Authors: Xiuling Lu
Funding: $156,000
2024-01-01 - 2025-12-31
Nanoparticle-Based Intraperitoneal Delivery of Combined Chemo-Brachytherapy for Treatment of Ovarian Cancer Metastases
Sponsor: DHHS/NIH/National Cancer Institute/NAMI Therapeutics
Authors: Xiuling Lu
Funding: $135,643
2019-09-01 - 2021-08-31
CPPR: Microstructure Evaluation of Nanoparticles for Understanding Lyoprotection during the Freeze-Drying Process
Sponsor: Mixed Sources
Authors: Xiuling Lu
Funding: $110,000
2020-09-01 - 2023-08-31
Microfluidics enabled nanomanufacturing of advanced biocatalysts for biofuel cells
Sponsor: VPR - UCONN
Authors: Challa V Kumar, Rajeswari Kasi, Tai-hsi Fan, Yu Lei, Xiuling Lu
Funding: $50,000
2015-03-15 - 2016-03-14
Radionuclide Therapy of Metastic Ovarian Cancer with Mesoporous Nanoparticles: Translation of Results in Animal Models to Humans
Sponsor: University of Connecticut Health Center
Authors: Xiuling Lu
Funding: $50,000
2013-07-01 - 2014-12-31
Radionuclide therapy of metastatic ovarian cancer with mesoporous nanoparticles: translation of results in animal models to humans
Sponsor: Connecticut Institute For Clinical And Translational Science
Authors: Xiuling Lu
Funding: $50,000
2013-07-01 - 2014-07-01
Quercetin Nanoemulsions for Enhancing its Oral Bioavailability and Chemoprotective Effects
Sponsor: UConn Diet and Health Initiative
Authors: Xiuling Lu
Funding: $50,000
2012-05-01 - 2014-04-30
In Vitro Drug Release Assessment for Semi-Solid Products
Sponsor: Bausch Health US
Authors: Xiuling Lu
Funding: $49,350
2020-11-24 - 2022-12-31
In Vitro Drug Release Assessment for Semi-Solid Products
Sponsor: Bausch Health US
Authors: Xiuling Lu
Funding: $23,096
2022-02-01 - 2023-01-31
Nanoemulsions for Overcoming Hypoxia and Elevated Interstitial Fluid Pressure in Tumors to Enhance the Effects of Cancer Chemotherapy and Radiation Therapy
Sponsor: UConn Faculty Large Grant
Authors: Xiuling Lu
Funding: $21,000
2012-01-01 - 2012-12-30
A New Investigation on Cell Cryopreservation for Cell-Based Therapies
Sponsor: UConn Department of Pharmaceutical Sciences
Authors: Xiuling Lu
Funding: $20,000
2020-06-01 - 2021-05-31
Novel Sublingual Films for Medical Imaging Applications
Sponsor: UConn START PPOC Award
Authors: Xiuling Lu
Funding: $10,000
2019-02-01 - 2020-01-31
Bone Marrow Accumulation of Nanoparticles and the Interaction with Leukemia Stem Cells
Sponsor: Connecticut Innovations/Yale University
Authors: Xiuling Lu
Funding: $10,000
2017-09-01 - 2018-12-17
Inhibition of Leukimic Stem Cells using Doxorubicin-Loaded Nanoparticles
Sponsor: UConn START PPOC Award
Authors: Xiuling Lu
Funding: $10,000
2018-11-01 - 2019-10-31
Analysis of the anti-adhesion mechanism in ovarian cancer cells
Sponsor: Uconn Holster Program
Authors: Xiuling Lu, Brian Liang
Funding: $5,000
2014-05-20 - 2014-08-20
Nanoparticle delivery of oxygenated perfluorocarbon as a method of tumor hypoxia reduction in mice bearing human lung cancer xenografts
Sponsor: Summer Undergraduate Research Fund (SURF) Awards
Authors: Xiuling Lu, Sarah Warack
Funding: $4,000
2014-05-20 - 2014-08-20
Student-Centered Learning Platform-Student Educational Assistance Program
Sponsor: Center for Excellent Teaching and Learning Mini Gran
Authors: Xiuling Lu, Nathaniel M Rickles, Kathryn Wheeler
Funding: $825
2019-01-01 - 2019-12-31
NIPTE Consortium for Enhancing Drug Development and Regulatory Science
Sponsor: DHHS/FDA/Food and Drug Administration/National Institute of Pharmaceutical Technology and Education
Authors: Xiuling Lu
2024-09-01 - 2029-08-31
A New Platform for Nanostructured Diagnostic Material Application to Facilitate the Discovery of Early Diagnostic Biomarkers for Neurodegenerative Diseases
Sponsor: DHHS/NIH/National Institutes of Health/CrystalNeuro
Authors: Xiuling Lu
2024-04-01 - 2025-03-31
Exosome Loaded Antibiotics for Prophylaxis and Treatment of ESKAPE Bacterial Wound Infections
Sponsor: DOD/Department of Defense/Physical Sciences
Authors: Xiuling Lu
2024-01-01 - 2024-06-30
Elastic Liposomal Nanoparticles for Middle Ear Drug Delivery
Sponsor: DHHS/NIH/National Institutes of Health/Stanford University
Authors: Xiuling Lu
2024-07-01 - 2029-06-30
Nanoparticle-Based Drug Delivery Systems for Improving Chemo-/Radio--Therapeutic Effectiveness
Sponsor: American Association of Pharmaceutical Scientists
Authors: Xiuling Lu
2012-11-01 - 2013-10-31
A New Platform for Nanostructured Diagnostic Material Application to Facilitate the Discovery of Early Diagnostic Biomarkers for Neurodegenerative Diseases
Sponsor: DHHS/NIH/National Institutes of Health/CrystalNeuro
Authors: Xiuling Lu
2024-12-02 - 2026-12-01
Bioequivalance of Complex Nanoparticle Formulations: Influence of Plasma Protein Interactions
Sponsor: DHHS/FDA/Food and Drug Administration/National Institute of Pharmaceutical Technology and Education
Authors: Xiuling Lu
2014-01-01 - 2015-12-31
Nanoparticle-Mediated Inhibition of Acute Leukemic Stem Cells
Sponsor: American Foundation for Pharmaceutical Education
Authors: Xiuling Lu
2019-09-01 - 2020-08-31
Discriminative In Vitro Release Methods for Predicting In Vivo Performance of Liposomal Drug Products
Sponsor: DHHS/FDA/Food and Drug Administration/National Institute of Pharmaceutical Technology and Education
Authors: Xiuling Lu
2014-09-01 - 2016-08-31
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases
Sponsor: DHHS/NIH/National Institutes of Health/NAMI Therapeutics
Authors: Xiuling Lu
2021-09-01 - 2023-08-31
Center for Collaborative Research on Complex Generics
Sponsor: DHHS/FDA/Food and Drug Administration/National Institute of Pharmaceutical Technology and Education
Authors: Xiuling Lu
2020-09-01 - 2025-08-31
Co-Delivery of Oxygen and Chemotherapy with Nanoparticles for Enhanced Chemoradiotherapy
Sponsor: DHHS/NIH/National Institutes of Health
Authors: Xiuling Lu
2020-07-01 - 2025-06-30
Neutron-Activatable Nanoparticles for Targeted Radionuclide Therapy of Tumors
Sponsor: Ford Foundation
Authors: Xiuling Lu
2014-09-01 - 2017-08-31
Activatable Nanoparticles for Radiotherapy of Metastatic Ovarian Cancer
Sponsor: American Cancer Society
Authors: Xiuling Lu
2014-07-01 - 2018-06-30
Adjuvant-Containing Nanocarriers for Synergetic Cancer Therapy
Sponsor: Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation
Authors: Xiuling Lu
2013-01-01 - 2013-12-31
Soft Robotics and Real Time Imaging for Assessing the Swallowability of Pharmaceutical Dosage Forms
Sponsor: DHHS/FDA/Food and Drug Administration/Stanford University
Authors: Xiuling Lu
2022-09-01 - 2025-08-31
Tumor-Specific Delivery of Radiotherapeutic Nanoparticles for Metastatic Ovarian Cancer
Sponsor: Mary Kay Foundation
Authors: Xiuling Lu
2014-07-01 - 2016-06-30
Tumor-specific nanoparticle-based internal radiation therapy combined with chemotherapy or immunotherapy for treating metastatic peritoneal cancers
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2022-04-01 - 2027-03-31
Cutting the Root: Inhibiting Chemoresistant Cancer Stem Cells using Nanoparticle-Mediated Drug Delivery
Sponsor: DHHS/NIH/National Institutes of Health
Authors: Xiuling Lu
2016-09-01 - 2021-08-31
Activatable Nanoparticles for Radiotherapy of Metastatic Ovarian Cancer
Sponsor: American Cancer Society
Authors: Xiuling Lu
2015-01-01 - 2018-12-31
Dexamethasone-Perfluorcarbon Nanoemulsions as a Pediatric Nanomedicine for Acute Lymphoblastic Leukemia
Sponsor: Hood (Charles H.) Foundation
Authors: Xiuling Lu
2013-07-01 - 2015-06-30
Targeting Cancer Stem Cells using Nanoparticle-Mediated Drug Delivery
Sponsor: CT Department of Public Health
Authors: Xiuling Lu
2015-09-01 - 2017-08-31
Adjuvant-Containing Nanocarriers for Synergetic Cancer Therapy
Sponsor: DOD/Department of Defense
Authors: Xiuling Lu
2013-09-30 - 2015-03-31
Effect of Particle Size on the Tumor-Specific Delivery of Mesoporous Silica Nanoparticles
Sponsor: American Foundation for Pharmaceutical Education
Authors: Xiuling Lu
2023-06-01 - 2024-08-31
Radionuclide Therapy of Metastatic Ovarian Cancer with Mesoporous Nanoparticles
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2013-07-01 - 2018-06-30
Apple SEDS: Improving Anti-Inflammatory Function and Gastrointestinal Health
Sponsor: USDA/National Institute of Food and Agriculture
Authors: Xiuling Lu
2014-11-01 - 2016-10-31
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases
Sponsor: DHHS/NIH/National Institutes of Health/NAMI Therapeutics
Authors: Xiuling Lu
2018-09-01 - 2019-08-31
Evaluating the Impact of Preservative and Surfactant Content variations in Otic Formulations
Sponsor: DHHS/FDA/Food and Drug Administration/Stanford University
Authors: Xiuling Lu
2024-09-01 - 2026-08-31
Nanoparticle-based Intraperitoneal Delivery of Combined Chem-brachytherapy for Treatment of Ovarian Cancer Metastases
Sponsor: DHHS/NIH/National Cancer Institute/NAMI Therapeutics
Authors: Xiuling Lu
2019-09-01 - 2020-08-31
Polymeric Nanoparticle Systems for Improving Cancer Therapy
Sponsor: SolMic Research GmbH
Authors: Xiuling Lu
2017-07-01 - 2022-06-30
Dissolution Methods for Predicting Bioequivalence of Long-acting Levonorgestrel Intrauterine Systems
Sponsor: DHHS/FDA/Food and Drug Administration
Authors: Xiuling Lu
2015-09-01 - 2020-08-31
Neutron-Activatable Mesoporous Silica Nanoparticles for Targeted Radionuclide Therapy of Peritoneal Metastases
Sponsor: American Foundation for Pharmaceutical Education
Authors: Xiuling Lu
2015-09-01 - 2016-08-31
Oxygen-Enhanced Radiochemotherapy: Optimization and Mechanism
Sponsor: DHHS/NIH/National Institutes of Health
Authors: Xiuling Lu
2020-09-01 - 2025-08-31
Tumor-specific delivery of nanoparticle-based brachytherapy combined with nano-chemotherapy or immunotherapy for metastatic ovarian cancer
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2021-04-01 - 2026-03-31
Neutron-Activatable Nanoparticles for Targeted Radionuclide Therapy of Tumors
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2012-07-01 - 2014-06-30
Quercetin Self-Nanoemulsifying Drug Delivery Systems for Improved Chemoprevention
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2014-04-01 - 2016-03-31
Nanoparticle-Mediated Inhibition of Acute Leukemic Stem Cells
Sponsor: American Foundation for Pharmaceutical Education
Authors: Xiuling Lu
2020-09-01 - 2021-08-31
Novel LAAM Formulations to Treat Opioid Use Disorder
Sponsor: DHHS/NIH/National Institute on Drug Abuse/Virginia Commonwealth University
Authors: Xiuling Lu
2019-04-01 - 2024-03-31
Targeting Cancer Stem Cells using Nanoparticle-Mediated Drug Delivery
Sponsor: CT Department of Public Health
Authors: Xiuling Lu
2014-09-01 - 2016-08-31
Nanoparticle-Based Intraperitoneal Delivery of Combined Chemo-Brachytherapy for Treatment of Ovarian Cancer Metastases
Sponsor: DHHS/NIH/National Institutes of Health/NAMI Therapeutics
Authors: Xiuling Lu
2019-04-01 - 2020-03-31
Understanding the Intracellular Distribution of Nanocarriers and the Delivered Drug for Physiology-Guided Nanomaterial Design and Evaluation
Sponsor: NSF/National Science Foundation
Authors: Xiuling Lu
2017-07-01 - 2020-08-31
Nanoparticle-Mediated Inhibition of Leukemic Stem Cells
Sponsor: Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation
Authors: Xiuling Lu
2020-01-01 - 2021-12-31
Tumor-Specific Radiotherapy for Peritoneal Metastases from Ovarian Cancer
Sponsor: American Cancer Society
Authors: Xiuling Lu
2020-07-01 - 2022-06-30
Dissolution Methods for Evaluating Generic Preparations of Ophthalmic Suspensions
Sponsor: Lannett
Authors: Xiuling Lu
2016-07-01 - 2016-12-31
Intraperitoneal Delivery of Targeted Nanoparticles for Metastatic Ovarian Cancer
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2014-04-01 - 2016-03-31
Neutron-Activatable Nanoparticles for Targeted Radionuclide Therapy of Tumors
Sponsor: American Association of Colleges of Pharmacy
Authors: Xiuling Lu
2013-01-02 - 2014-01-01
Emerging manufacturing technologies for monodispersed complex particulate pharmaceuticals: risk-based quality assessments facilitated by artificial intelligence and digital transformation
Sponsor: DHHS/FDA/Food and Drug Administration
Authors: Xiuling Lu
2021-09-01 - 2026-08-31
Tumor-Specific Radiotherapy for Peritoneal Metastases from Ovarian Cancer
Sponsor: American Cancer Society
Authors: Xiuling Lu
2021-01-01 - 2022-12-31
Boron-Assisted Bioresponsive Lipid Nanoparticles for Improved Gene Delivery
Sponsor: DHHS/NIH/National Institutes of Health
Authors: Xiuling Lu
2024-04-01 - 2029-03-31
A New Platform for Nanostructured Diagnostic Material Application to Facilitate the Discovery of Early Diagnostic Biomarkers for Neurodegenerative Diseases
Sponsor: DHHS/NIH/National Institutes of Health/CrystalNeuro
Authors: Xiuling Lu
2023-04-01 - 2024-03-31
Tumor-Specific Radiotherapy and Immunomodulation for Eliminating Metastatic Ovarian Cancer
Sponsor: DOD/Army/Army Medical Research Acquisition Activity
Authors: Xiuling Lu
2024-07-01 - 2027-06-30
Intraperitoneally-Administered Radionuclide-Containing Nanoparticles for Treating Metastatic Ovarian Cancer
Sponsor: DHHS/NIH/National Institutes of Health/NAMI Therapeutics
Authors: Xiuling Lu
2022-07-01 - 2024-06-30
Tumor-specific internal radiation therapy and immunomodulation for treating metastatic peritoneal cancers
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2023-09-01 - 2028-08-31
Tumor-specific internal radiation therapy and immunomodulation for treating metastatic peritoneal cancers
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Xiuling Lu
2025-07-01 - 2030-06-30
Assessing the Swallowability of Pharmaceutical Dosage Forms using Soft Robotics
Sponsor: DHHS/FDA/Food and Drug Administration/National Institute of Pharmaceutical Technology and Education
Authors: Xiuling Lu
2021-09-01 - 2024-08-31
Intraperitoneally-administered radionuclide-containing Nanoparticles in combination with immunotherapy for treating peritoneal cancer
Sponsor: DHHS/NIH/National Cancer Institute/NAMI Therapeutics
Authors: Xiuling Lu
2024-07-01 - 2025-06-30
Novel Formulations for Mitigating QT Interval Prolongation during the Treatment of Substance Use Disorder
Sponsor: DHHS/NIH/National Institute on Drug Abuse
Authors: Xiuling Lu
2023-04-01 - 2025-03-31
Dual Delivery of Oxygen and Chemotherapy with Nanocapsules for Enhanced Chemoradiotherapy
Sponsor: DHHS/NIH/National Institutes of Health
Authors: Xiuling Lu
2018-09-01 - 2023-08-31